DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pioglitazone for Hepatic Steatosis in HIV/HCV Co-infection.

Author(s): Matthews L(1), Kleiner D(2), Chairez C(3), McManus M(4), Nettles MJ(5), Zemanick K(6), Morse C(7), Benator D(8), Kovacs J(9), Hadigan C(10).

Affiliation(s): Author information: (1)National Institutes of Health, Critical Care Medicine, Bethesda, Maryland, United States ; Lmatth3@gmail.com. (2)National Institutes of Health, National Cancer Institute, Bethesda, Maryland, United States ; kleinerd@mail.nih.gov. (3)National Institutes of Health, NIAID, Bethesda, Maryland, United States ; chairezc@niaid.nih.gov. (4)National Institutes of Health, Critical Care Medicine, Bethesda, Maryland, United States ; maryellen.mcmanus@nih.gov. (5)VAMC, Washington DC, Infectious Diseases, Medicine, Washington, District of Columbia, United States ; Mary.Nettles@va.gov. (6)NIH Clinical Center, Nursing, Bethesda, Maryland, United States ; zemanickk@niaid.nih.gov. (7)NIH Clinical Center, Critical Care Medicine, AIDS Section , 9000 Rockville Pike, Building 10/5A06 , MSC 1403 , Bethesda, Maryland, United States , 20892-1403 , 301-496-6028 , 301-480-1735 ; cmorse@cc.nih.gov. (8)VAMC, Washington DC, Infectious Diseases, Medicine, Washington, District of Columbia, United States ; debra.Benator@va.gov. (9)NIH Clinical Center, Critical Care Medicine, AIDS Section , 9000 Rockville Pike, Building 10/5A06 , MSC 1403 , Bethesda, Maryland, United States , 20892-1403 , 301-496-6028 , 301-480-1735 ; jkovacs@mail.nih.gov. (10)National Institutes of Health, NIAID , 10 Center Drive , Rm 11C103 , Bethesda, Maryland, United States , 20892 , 301-594-5754 ; hadiganc@niaid.nih.gov.

Publication date & source: 2015, AIDS Res Hum Retroviruses. ,

Background Chronic hepatitis C infection frequently coexists with human immunodeficiency virus (HIV) and together are associated with increased hepatic steatosis. Steatosis is a risk factor for progression of liver disease and may persist despite a sustained virologic response to Hepatitis C treatment. Therefore, therapies to target hepatic steatosis are important for individuals with HIV and hepatitis C virus (HCV) co-infection. Methods We completed a 48 week, randomized, double-blind, placebo-controlled trial of pioglitazone (45 mg/d) in 13 subjects with HIV/HCV co-infection. The primary outcome variable was hepatic fat content, measured by magnetic resonance spectroscopy (MRS) imaging. Results Individuals randomized to pioglitazone had a significant decrease in hepatic fat content measured by MRS from baseline (15.1±7.0%) to week 48 (7.6±3.9%), with a mean difference of -7.4% (p=0.02, n=5). There was no significant change in hepatic fat content with placebo. Glycemic control as measured by oral glucose challenge improved significantly with pioglitazone (p=0.047). Though not statistically significant, there were trends towards improved alanine aminotransferase (ALT) and histopathologic grade of steatosis in subjects who received pioglitazone. Pioglitazone was well-tolerated and no one discontinued due to side effects. Conclusions This study demonstrates that 48 weeks of pioglitazone therapy, and not placebo, results in significant reductions in hepatic fat content as measured by MRS in subjects with HIV and HCV co-infection and hepatic steatosis. This small study shows that pioglitazone helps ameliorate steatosis in the context of HIV/HCV co-infection.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017